Simcere jumps on pharma licensing deal with Boehringer Ingelheim

Simcere Pharmaceutical

28/01/2026 07:35

** Shares of Simcere Pharmaceutical Group 2096.HK rise 5.9% to HK$12.65, the highest level since December 29

** Stock on track for the biggest one-day pct gain since November 13, rising for the third consecutive session

** Simcere says its unit has entered into an exclusive licensing agreement with German pharma co Boehringer Ingelheim, which it will have the exclusive global rights outside Greater China of SIM0709 - a bispecific antibody for inflammatory bowel disease

** The group is eligible to receive an upfront payment of 42 mln euros ($50.39 mln) and success-based development, regulatory and sales milestones of up to 1.016 bln euros

** The group is also eligible for tiered royalties on net sales outside Greater China - co

** YTD, stock up 1.2%, Hang Seng Biotech Index .HSBIO up 12.1%

($1 = 0.8335 euros)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))